FILING ANALYSIS · THURSDAY, NOVEMBER 12
TScan Therapeutics, Inc. TCRX — 8-K: Results of Operations and Financial Condition
neutral
TScan Therapeutics has paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital and is seeking strategic partnerships, while advancing its in vivo-engineered TCR-T cell therapy candidates for solid tumors, with cash and cash equivalents expected to fund operations into the fourth quarter of 2027
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →